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Background: In chronic hepatitis C virus (HCV) infection, liver tissue pathology and HCV genotype are important
determinants of clinical and/or treatment-related outcome. Although consistent epidemiological and/or
molecular-biological clues derived from different studies on single virus-host interactions are meanwhile published,
the in vivo transcriptional responses and cellular pathways affected in >1 key aspects of the disease or treatment
process are far from being understood.
Methods: Microarray analysis was performed in peripheral whole blood (PB) samples from 36 therapy-naïve
HCV-infected patients with known liver histology. Linear regression analysis identified gene expression profiles
significantly correlating (P< 0.015) with ≥1 out of 7 variables: sustained viral response (SVR), viral non-response (NR),
end of treatment viral response (ETR), viral breakthrough (VB), HCV genotype (Gt. 1 vs. Gt. 2/3), stage of hepatic
fibrosis [St. 0/1 vs. St. 2/3/4] and grade of hepatic inflammation (Gr. 0/1 vs. Gr. 2/3/4). Correlation values across all
seven contrasts were considered for hierarchical clustering (HCL).
Results: A total of 1,697 genes showed ≥1 significant correlation results and genes involved in cell differentiation
(183), immune response (53), and apoptosis (170) were leading fractions. HCL grouped the genes into six major
clusters. Functional annotation analysis using DAVID (http://david.abcc.ncifcrf.gov) revealed that expression profiles
that best linked these variables were highly enriched in cytokine/chemokine activity (Fisher-exact P< 0.0001) and
specific biological module-centric algorithms finally led our focus on four out of fifty-three immune response genes:
SMAD family member 3 (SMAD3), interleukin 1 receptor accessory protein (IL1RAP), tumor necrosis factor receptor
superfamily member 1A (TNFRSF1A), and chemokine ‘C-C motif’ receptor 5 (CCR5). Of those, TNFRSF1A and CCR5
showed significant correlation with two out of seven variables based on microarray and/or quantitative real-time
polymerase chain reaction (qRT-PCR) data.
Conclusion: We identified molecular targets of the innate and adaptive immune system and validated their
transcriptional specificity in vivo suggesting significant involvement in two unique outcomes during HCV treatment.
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Table 1 Distribution of patients across seven categorical
disease-/therapy-related outcomes
Symbol Categorical title Count (n)
SVR Sustained viral response 16/36
ETR End of treatment viral response 7/36
VB Viral breakthrough 5/36
NR Viral non-response 8/36
Gt. 2,3 HCV genotype 2 or 3 6/36
Fibrosis St. 0,1 Histological stage of hepatic
Fibrosis 0 or 1
21/36
(Batts-Ludwig classification)
Inflammation Gr. 0,1 Histological grade of hepatic
Inflammation 0 or 1
23/36
(Batts-Ludwig classification)
Table 1 gives the numerical distribution of patients (n = 36), whose samples
were subjected to microarray analysis at baseline, among seven groups
representing categorical variables as defined under the Methods section.
Katsounas et al. European Journal of Medical Research 2012, 17:9 Page 2 of 6
http://www.eurjmedres.com/content/17/1/9Background
Hepatitis C virus (HCV) is estimated to persistently infect
about 170 million people worldwide [1]. Histological grade
of hepatic inflammation and stage of hepatic fibrosis as well
as HCV genotype (Gt.) are considered significant determi-
nants of clinical outcome in terms of progression of liver
disease, and/or response to treatment in patients with
chronic HCV infection (cHCV) as: (1) persistent he-patic
inflammation is considered a major determinant of liver
fibrosis progression towards cirrhosis [2]; (2) previous re-
search has detected an association between advanced
hepatic fibrosis and lower rates of successful response (sus-
tained viral response (SVR)) to Interferon-alpha [3] or pegy-
lated Interferon-alpha and Ribavirin (Peg-IFN-α/RBV) [4];
and (3) patients infected with Gt.2 or Gt.3 (80%) regularly
achieve higher SVR rates relative to those infected with
Gt.1 or Gt.4 (50%) [5]. To date, molecular targets/pathways
significantly involved in multiple disease and/or treatment
response determining host interactions with HCV have not
been systematically studied or characterized. In this study,
we analyzed gene expression profiles in peripheral whole
blood (PB) of therapy-naïve HCV-infected subjects that
underwent liver biopsy in order to identify gene expression
patterns reflective of host biology that is linked to ≥1 clin-
ical and/or viral stratification clusters. To this end, rigorous
multicontrast linear regression analysis was performed on
gene expression profiles against seven variables reflecting
the state of cHCV with or without therapy. Our final results
demonstrated that tumor necrosis factor receptor super-
family member 1A (TNFRSF1A) and chemokine ‘C-C
motif ’ receptor 5 (CCR5) correlated significantly with two
out of seven variables. These findings, which have also been
successfully validated by quantitative real-time polymerase
chain reaction (qRT-PCR) in a fraction of patients, repre-
sent a promising basis for future molecular research aimed
to provide comprehensive insights into genes/pathways
with multiple in vivo impacts in viral hepatitis and/or de-
velop anti-HCV therapies that target these genes/pathways.
Methods
Study subjects
Therapy-naïve Caucasian patients with cHCV (n=36)
received Peg-IFN-α2a (PegasysW/Roche: 180 μg/week) or
Peg-IFN-α2b (PEG-IntronW/Schering-Plough: 1.5 μg/kg/
week) and Ribavirin (RBV, RebetolW/Schering-Plough,
1000–1200 mg/d) for 48 weeks (Gt.1) or 24 weeks (Gt.3)
and were followed up for 24 weeks post treatment at the
University Hospital in Essen, Germany. All donors signed
informed consents approved by the local board for ethics.
Liver biopsy
Liver biopsies were obtained from all 36 patients prior to
enrollment as part of their standard clinical assessments.
All 36 specimens were evaluated using the Batts-LudwigGrading (BL-G) and Staging (BL-S) system for viral hepa-
titis [6].
Laboratory studies
Quantitative HCV RNA was performed 12 h before
administration of the first dose of Peg-IFN-α and later
during each study visit. Liver chemistry and safety labora-
tory tests were performed 12 h prior to treatment initi-
ation and during each study visit.
Microarray analysis
RNA (PAXgene-Blood-RNA-Kit, Qiagen, Hilden, Germany)
isolated from PB was collected 12 h before the first
injection of Peg-IFN-α directly into PAXgene-Blood-RNA-
Tubes (Qiagen, Hilden, Germany). Total RNA, cRNA syn-
thesis, and labeling along with hybridization to the
U133A_2 or U133A arrays (Affymetrix, St Clara, CA, USA)
were performed according to the manufacturer’s protocol.
Gene expression values (log2) were determined using a cor-
rection for probe GC content, RMA background subtrac-
tion, and Quantile normalization. Chip-type-related batch
effect was removed by regression analysis (PARTEK Gen-
omics Suite).
Thirty-six patients were assigned to seven unique categor-
ies based on the criteria shown in Table 1: therapy outcome
(SVR; NR, viral non-response; VB, viral breakthrough; ETR,
viral relapse or end of treatment viral response), HCV geno-
type (Gt. 1 vs. Gt. 2/3), histological stage of hepatic fibrosis
(St. 0/1 vs. St. 2/3/4), and histological grade of hepatic in-
flammation (Gr. 0/1 vs. Gr. 2/3/4). In a first step, gene ex-
pression profiles in PB were subjected to linear regression
analysis against the abovementioned seven categorical vari-
ables. Then, expression profiles of genes that passed the strict
statistical cutoff of P<0.015 in at least one contrast were
selected and further subjected to unsupervised hierarchical
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across all seven contrasts. Furthermore, functional annota-
tion analysis using DAVID [7] was performed to identify bio-
logical activity that these expression profiles were most
highly enriched in. Specific biological module-centric algo-
rithms finally led our focus on four genes significantly
involved in ‘immune response’. In a second step, we selected
two out of those four genes by filtering the respective micro-
array data based on which expression profiles had reached
statistical significance in at least one additional contrast.
These results were validated by PCR in a fraction of patients
(n=9), of which RNA samples were currently available.
Details on gene selection algorithms and clustering along
with statistical degree and magnitude of associations are
provided under the Results section. Correlation heat maps
as well as clustering of microarray data have been performed
using PARTEK Genomics Suite.
qRT-PCR
Real-time detection of target gene messenger RNAs
(mRNAs) with one-step quantitative PCR was performed
on the Rotor-Gene 2000 real-time amplification system
(Corbett Research). One-step qRT-PCR was carried out with
the QuantiTect SYBR Green RT-PCR Kit (Qiagen) accord-
ing to the manufacturer’s instructions. For the mRNA popu-
lation per 1 gene, copy numbers were normalized to the
number of beta-actin (β-actin) transcripts. Furthermore, theFigure 1 Unsupervised (hierarchical) clustering grouped 1,697 genes
categorical variables (P<0.015) into six major clusters. Red color reflecTNFRSF1A and CCR5 gene transcripts were quantified by
qRT-PCR using specific QuantiTect Primer Assays
(Qiagen).
Statistical analysis
Linear regression analysis was performed using one-way
ANOVA. Statistics and Graphics were performed in PAR-
TEK Genomics Suite. The significance cutoff was chosen
not to exceed 5% (P<0.05). As shown elsewhere [8], for
analysis checking two contrasts at once we relaxed P to ≤0.1
only for one contrast in order not to risk missing significant
biology and obtain a slightly larger gene set for validation
qRT-PCR.
Results
In this study, we analyzed expression patterns of genes sig-
nificantly correlating with one or more HCV-related para-
meters, liver disease outcomes and/or responses to anti-
HCV treatment. More specifically, gene expression profiles
in PB of therapy-naïve patients with cHCV were subjected
to linear regression analysis against seven categorical vari-
ables shown in Table 1. Gene expression profiles (n=1,697)
that reached at least one highly significant correlation result
(r > 0.4 or r<−0.4, P<0.015) were selected and further sub-
jected to unsupervised hierarchical clustering (HCL) using
linear regression values calculated across all seven contrasts
(Figure 1). HCL grouped the genes into six major clusterssignificantly correlating with ≥1 of the displayed seven
ts (+) correlation; green color reflects (−) correlation.
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expression profiles, clinic- or therapy-related outcomes and
viral characteristics. Genes involved in immune response
(n=53), cell differentiation (n=183), and apoptosis
(n=170) were leading fractions across these clusters based
on functional annotation analysis using DAVID [7]. Expres-
sion profiles that best linked these parameters were highly
enriched in ‘cytokine/chemokine activity’ (DAVID [7], Fisher
exact P<0.0001).
Then, we focused on four out of the fifty-three genes
involved in ‘immune response’ through specific biological
module-centric algorithms provided by DAVID [7], that is
SMAD family member 3 (SMAD3), interleukin 1 receptor
accessory protein (IL1RAP), TNFRSF1A, and CCR5.
Among those, CCR5 gene expression (microarray) showed
a strong positive correlation with SVR (r=0.29, P=0.08)
and an inverse correlation with VB (r=−0.38, P=0.02,
Additional file 1: Table S1) at baseline. TNFRSF1A gene ex-
pression (microarray) exhibited positive correlation with
SVR (r =0.41, P=0.01) and an inverse correlation with NR
(r=−0.35, P=0.03, Additional file 1: Table S1) at baseline.
In line with these findings were the results from the exact
same type of analysis including gene expression data gener-
ated by qRT-PCR. Thus, CCR5 gene expression (qRT-PCR)
showed a positive correlation with SVR (r =0.78, P=0.01)
and an inverse correlation with VB (r = −0.58,
P = 0.09, Additional file 2: Table S2) at baseline.
TNFRSF1A gene expression (qRT-PCR) exhibited a
positive correlation with SVR (r = 0.64, P = 0.06) and
an inverse correlation with NR (r = −0.57, P = 0.1,
Additional file 2: Table S2) at baseline. Since only a
small count of samples were available for qRT-PCR
(n = 9), caution should be exerted when interpreting
the P; therefore, mainly correlation values should be
used as comparable measures between microarray
and qRT-PCR results.
Knowing this, we should also note that qRT-PCR data
often showed a lower P relative to microarray data due
to the higher correlation values calculated by one-way
ANOVA in all contrasts. However, results obtained for
TNFRSF1A and CCR5 on the level of both microarray
and qRT-PCR analyses are statistically tight. Conse-
quently, our approach considering these genes important
players for multiple in vivo outcomes (despite some
associations with the abovementioned variables at a
relaxed P of ≤0.1 [8] in different settings, i.e. microarray
vs. qRT-PCR) likely identified active and meaningful bio-
logical relationships. Results for SMAD3 reached signifi-
cance in no contrast based on qRT-PCR expression
values and showed predominantly inconsistent trends
relative to microarray data (Additional file 1: Tables S1
and Additional file 2: Table S2). Interestingly, IL1RAP
showed only on the level of qRT-PCR data analysis a
positive correlation with SVR (r = 0.75, P= 0.01).Taken together, this study identified molecular mar-
kers/pathways of the innate and adaptive immune sys-
tem that potentially exert multifaceted in vivo roles in
cHCV as indicated by statistical correlations between
two unique disease-related outcomes and gene expres-
sion profiles detected by microarray analysis and vali-
dated by qRT-PCR.
Discussion
The present study was aimed to identify human genes/
pathways participating in multiple host interactions with
HCV in vivo. The analytical design chosen provided a
unique opportunity to use the microarray-technique as a
molecular readout for the differential regulation of
genes/pathways with diverse potential implications in
cHCV. Thus, pattern analysis of microarray data based
on gene expression significantly correlating with one or
more viral characteristics, histological liver pathologies,
and/or final treatment responses led to identification of
specific gene clusters strongly associated with the cyto-
kine/chemokine activity in vivo. These observations ap-
pear biologically consistent with previous research
linking liver disease and treatment outcome during
cHCV to responses of both the innate and adaptive im-
mune system orchestrated by networks of cytokines and
chemokines [9,10]. Particularly, various cytokines and
chemokines are reportedly involved in affecting host sus-
ceptibility to developing chronic hepatitis C or response
of cHCV to IFN-α therapy [11,12].
Using microarray analysis, combined with functional an-
notation tools such as DAVID [7], we detected specific
changes in gene expression of four molecular markers
assigned to the functional annotation category ‘immune
response’, that is SMAD3, IL1RAP, TNFRSF1A, and
CCR5, which exhibited significant correlation with two
categorical variables representing unique therapy out-
comes. Validation qRT-PCR confirmed these results for
TNFRSF1A and CCR5. In contrast, linear regression ana-
lysis using qRT-PCR data for SMAD3 did not detect any
significance; therefore, SMAD3 has been omitted from the
Discussion section. As specific interactions between HCV
and SMAD3 have been previously identified but are, how-
ever, beyond this article’s scope, interested readers are re-
ferred for details to the respective original literature [13].
Moreover, increased TNFRSF1A gene expression at
baseline was found in significant correlation with HCV
elimination in terms of SVR and inverse relation to HCV
persistence due to complete viral non-response (NR, that
is non-ETR or non-VB). These observations are in agree-
ment with previous publications showing up-regulation of
TNFRSF1A expression in peripheral dendritic cells of
HCV-infected patients who reach SVR [14].
In recent years, increasing amounts of evidence have
indicated that spontaneous HCV clearance or successful
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helper 1 (Th1) lymphocyte-related cytokine/chemokine
profile including CCL5 and its specific receptor CCR5
[15]. In this light, the positive correlation between CCR5
gene expression levels and SVR as well as the inverse
correlation between CCR5 gene expression and VB,
which is the most immediate type of treatment failure,
both observed in the present study, strongly suggest the
good prognostic value along with the potentially favor-
able biological role of increased CCR5 expression in the
peripheral blood at baseline.
There are several limitations of this study that warrant
comment. First, patients in relative low numbers failed
to clear HCV due to ETR (n= 7) or VB (n= 5), which
may have affected the statistical power of the linear re-
gression model and introduced errors in calculation of
significance in ETR- and/or VB-based contrasts. Second,
this study was able to provide confirmation of significant
correlations against validated results via qRT-PCR in
only 25% (9/36) of patients whose samples were origin-
ally subjected to microarray analysis. Third, protein ex-
pression has not been investigated for identified gene
targets; thus, posttranscriptional expression and true
level of functional importance of these genes remains
obscure. Future work will address these concerns in on-
going clinical trials with larger numbers of HCV-
infected subjects treated with Peg-IFN-α/RBV and/or
new direct-acting antiviral agents.Conclusions
In conclusion, this study provides foundation for greater
understanding of the multifaceted role of the immune
system in the outcome of chronic hepatitis C by associ-
ating patient stratification based on standard clinical
variables with biologically significant genes/pathways
likely involved in numerous key aspects of the disease
and treatment process in vivo.Additional files
Additional file 1: Table S1. Final linear regression analysis results based
on microarray data at baseline [16].
Additional file 2: Table S2. Final linear regression analysis results based
on qRT-PCR data at baseline [16].Abbreviations
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